Updated Jul 16, 2026 · Last SEC filing 2026-07-14
Bicara Therapeutics Inc. (BCAX) has filed 18 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-14. 3 Form 8-K material event filings were reported by BCAX in the last 90 days. 14 Form 144 notices of proposed sale were filed for BCAX stock. InsiderAlpha tracks every BCAX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0002023658 |
| Form 4 filings (90d) | 18 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 14 |
| Latest Form 4 filing | 2026-07-14 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire | Chief Executive Officer | M — Option exercise [10b5-1] | 10.0K | $3.79 | $38K | SEC | |
| Mazumdar Claire | Chief Executive Officer | S — Open-market sale [10b5-1] | 28 | $29.68 | $831 | SEC | |
| Mazumdar Claire | Chief Executive Officer | S — Open-market sale [10b5-1] | 10.0K | $28.42 | $283K | SEC | |
| Cohlhepp Ryan | President and COO | S — Open-market sale | 536 | $29.00 | $16K | SEC | |
| Hyep Ivan | Chief Financial Officer | M — Option exercise | 12.5K | $3.79 | $47K | SEC | |
| Cohlhepp Ryan | President and COO | S — Open-market sale | 1.1K | $30.35 | $33K | SEC | |
| Hyep Ivan | Chief Financial Officer | S — Open-market sale | 830 | $30.31 | $25K | SEC | |
| Cohlhepp Ryan | President and COO | M — Option exercise | 18.8K | $3.79 | $71K | SEC | |
| Cohlhepp Ryan | President and COO | S — Open-market sale | 4.3K | $29.80 | $128K | SEC | |
| Hyep Ivan | Chief Financial Officer | S — Open-market sale | 22.8K | $28.60 | $651K | SEC | |
| Cohlhepp Ryan | President and COO | S — Open-market sale | 22.8K | $28.76 | $657K | SEC | |
| Hyep Ivan | Chief Financial Officer | S — Open-market sale | 4.4K | $29.82 | $132K | SEC | |
| Hyep Ivan | Chief Financial Officer | S — Open-market sale | 9.2K | $20.42 | $188K | SEC | |
| Hyep Ivan | Chief Financial Officer | M — Option exercise | 9.2K | $3.79 | $35K | SEC | |
| Mazumdar Claire | Chief Executive Officer | M — Option exercise | 15.0K | $3.79 | $57K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Bicara Therapeutics Inc. (BCAX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Mazumdar Claire | 17 | $1.19M |
| Cohlhepp Ryan | 14 | $1.51M |
| Hyep Ivan | 12 | $1.32M |
| Raben David | 3 | $147K |
| RA CAPITAL MANAGEMENT, L.P. | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in BCAX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live BCAX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.